Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122670929 | 12267092 | 9 | F | 20160919 | 20160414 | 20160929 | PER | US-PFIZER INC-2016197637 | PFIZER | 54.00 | YR | M | Y | 105.21000 | KG | 20160929 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122670929 | 12267092 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | 50 MG, CYCLIC (2 WEEKS ON/1 WEEK OFF) | 21938 | 50 | MG | CAPSULE, HARD | ||||||||
| 122670929 | 12267092 | 2 | SS | SUTENT | SUNITINIB MALATE | 1 | 50 MG, ALTERNATE DAY | 21938 | 50 | MG | CAPSULE, HARD | QOD | |||||||
| 122670929 | 12267092 | 3 | SS | SUTENT | SUNITINIB MALATE | 1 | 37.5 MG, CYCLIC, 2 WEEKS ON, 1 WEEK OFF | 21938 | 37.5 | MG | CAPSULE, HARD | ||||||||
| 122670929 | 12267092 | 4 | SS | SUTENT | SUNITINIB MALATE | 1 | 37.5 MG, ALTERNATE DAY | 21938 | 37.5 | MG | CAPSULE, HARD | QOD | |||||||
| 122670929 | 12267092 | 5 | SS | SUTENT | SUNITINIB MALATE | 1 | Oral | 37.5 MG, DAILY | 21938 | 37.5 | MG | CAPSULE, HARD | |||||||
| 122670929 | 12267092 | 6 | SS | SUTENT | SUNITINIB MALATE | 1 | Oral | 37.5 MG, CYCLIC (2 WKS ON ONE WK OFF QD) | 21938 | 37.5 | MG | CAPSULE, HARD | |||||||
| 122670929 | 12267092 | 7 | C | TEMAZEPAM. | TEMAZEPAM | 1 | UNK | 0 | |||||||||||
| 122670929 | 12267092 | 8 | C | FLECAINIDE | FLECAINIDE | 1 | UNK | 0 | |||||||||||
| 122670929 | 12267092 | 9 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | UNK | 0 | |||||||||||
| 122670929 | 12267092 | 10 | C | LISINOPRIL. | LISINOPRIL | 1 | 20 MG, DAILY | 0 | 20 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122670929 | 12267092 | 1 | Metastatic renal cell carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122670929 | 12267092 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122670929 | 12267092 | Asthenia | |
| 122670929 | 12267092 | Decreased appetite | |
| 122670929 | 12267092 | Fatigue | |
| 122670929 | 12267092 | Fluid intake reduced | |
| 122670929 | 12267092 | Hypertension | |
| 122670929 | 12267092 | Liver function test increased | |
| 122670929 | 12267092 | Nasopharyngitis | |
| 122670929 | 12267092 | Palmar-plantar erythrodysaesthesia syndrome | |
| 122670929 | 12267092 | Temperature intolerance |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122670929 | 12267092 | 1 | 20160321 | 0 | ||
| 122670929 | 12267092 | 2 | 20160502 | 0 | ||
| 122670929 | 12267092 | 3 | 20160619 | 0 | ||
| 122670929 | 12267092 | 4 | 20160321 | 0 |